PMID- 25402559
OWN - NLM
STAT- MEDLINE
DCOM- 20150814
LR  - 20190212
IS  - 1421-9778 (Electronic)
IS  - 1015-8987 (Linking)
VI  - 34
IP  - 5
DP  - 2014
TI  - IGF2R expression is associated with the chemotherapy response and prognosis of 
      patients with advanced NSCLC.
PG  - 1578-88
LID - 10.1159/000366361 [doi]
AB  - BACKGROUND: Insulin-like growth factor (IGF) pathway has been suggested as a new 
      molecular target for the treatment of cancer including Non-small cell lung cancer 
      (NSCLC). We postulated that IGF-2 receptor (IGF2R) may be associated with 
      treatment response and prognosis of NSCLC patients receiving chemotherapy. 
      METHODS: A total of 464 patients with inoperable advanced stage of NSCLC were 
      enrolled. All patients received platinum-based chemotherapy. Meanwhile, the IGF2R 
      expression in tumor samples was detected by Immunohistochemical analysis. The 
      IGF2R expression was inhibited in several human NSCLC cell lines (H292, A549, 
      NCI-H460, Calu-3 and NCI-H23) after small interfering RNA (siRNA) transfection 
      and the cellular biology behavior were evaluated. RESULTS: Of all NSCLC patients, 
      204 had high IGF2R expression and 260 had low IGF2R expression. The low IGF2R 
      expression was significantly associated with the smoking status, higher tumor 
      stage, and poorer differentiation status of these patients. Notably, we found 
      that the low IGF2R expression was closely associated with the chemotherapy 
      response in NSCLC patients. Patients with low IGF2R expressions had a poorer 
      prognosis than those with high IGF2R expressions. IGF2R inhibition by si-RNA 
      technique in NSCLC cell lines increased the proliferation, migration and invasion 
      abilities, but reduced the apoptosis rate. IGF2R silencing significantly enhanced 
      the chemo-resistance of NSCLC cell lines to cisplatin treatment. CONCLUSION: The 
      IGF2R expression in tumor is associated with the chemotherapy response and 
      prognosis of Patients with advanced NSCLC.
CI  - (c) 2014 S. Karger AG, Basel.
FAU - Tian, Zhennan
AU  - Tian Z
AD  - Department of Pathology, The Third Affiliated Hospital of Harbin Medical 
      University, Nangang District, Harbin, China.
FAU - Yao, Guodong
AU  - Yao G
FAU - Song, Hongtao
AU  - Song H
FAU - Zhou, Yang
AU  - Zhou Y
FAU - Geng, Jingshu
AU  - Geng J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141031
PL  - Germany
TA  - Cell Physiol Biochem
JT  - Cellular physiology and biochemistry : international journal of experimental 
      cellular physiology, biochemistry, and pharmacology
JID - 9113221
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptor, IGF Type 2)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Apoptosis/drug effects/genetics
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects/genetics
MH  - Cell Proliferation/drug effects/genetics
MH  - Cisplatin/pharmacology
MH  - Drug Resistance, Neoplasm/genetics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - RNA, Small Interfering/genetics
MH  - Receptor, IGF Type 2/*genetics
EDAT- 2014/11/18 06:00
MHDA- 2015/08/15 06:00
CRDT- 2014/11/18 06:00
PHST- 2014/09/01 00:00 [accepted]
PHST- 2014/11/18 06:00 [entrez]
PHST- 2014/11/18 06:00 [pubmed]
PHST- 2015/08/15 06:00 [medline]
AID - 000366361 [pii]
AID - 10.1159/000366361 [doi]
PST - ppublish
SO  - Cell Physiol Biochem. 2014;34(5):1578-88. doi: 10.1159/000366361. Epub 2014 Oct 
      31.